(Source: Cynapsus Therapeutics Inc) -- Webcast with accompanying slides to discuss these findings tomorrow at 7:30 a.m. Eastern time Top-line CTH-300 results expected in late Q3 or early Q4 -- TORONTO, July 18, 2016 (GLOBE NEWSWIRE) -- Cynapsus Therapeutics, Inc. (NASDAQ:CYNA) (TSX:CTH), a specialty central nervous system (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD), today announced positive open-label dose titration phase (DTP) results from the ongoing CTH-300 pivotal Phase 3 efficacy and safety trial (CTH-300). CTH-300...
↧